Having trouble accessing articles? Reset your cache.

Anturol meets overactive bladder endpoint

Antares Pharma Inc. (NYSE-A:AIS) said once-daily topical Anturol met the primary

Read the full 110 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE